Li–Fraumeni syndrome heterogeneity

• P. Gargallo ^[1] ; Y. Yáñez ^[2] ; V. Segura ^[1] ; A. Juan ^[1] ; B. Torres ^[1] ; J. Balaguer ^[1] ; S. Oltra ^[3] ; V. Castel ^[1] ; A. Cañete ^[1]
  1. [1] Pediatric Oncology, La Fe Hospital, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain
  2. [2] Clinical and Translational Oncology Research Group, La Fe Hospital, Valencia, Spain
  3. [3] Genetics Unit, La Fe Hospital, Valencia, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 7, 2020, págs. 978-988
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 1 Cita
• Resumen

  • Clinical variability is commonly seen in Li–Fraumeni syndrome. Phenotypic heterogeneity is present among different families affected by the same pathogenic variant in TP53 gene and among members of the same family. However, causes of this huge clinical spectrum have not been studied in depth. TP53 type mutation, polymorphic variants in TP53 gene or in TP53-related genes, copy number variations in particular regions, and/or epigenetic deregulation of TP53 expression might be responsible for clinical heterogeneity. In this review, recent advances in the understanding of genetic and epigenetic aspects influencing Li–Fraumeni phenotype are discussed.